• 1
    Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. J Am Coll Cardiol 2007; 50: 217395.
  • 2
    Alpert JS, Thygesen K, Antman EM, Bassand JP. Myocardial infarction redefined—a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36: 95969.
  • 3
    Bassand JP, Hamm CW, Ardissino D et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007; 28: 1598660.
  • 4
    Macrae AR, Kavsak PA, Lustig V et al. Assessing the requirement for the 6-hour interval between specimens in the American Heart Association classification of myocardial infarction in epidemiology and clinical research studies. Clin Chem 2006; 52: 8128.
  • 5
    Pope JH, Aufderheide TP, Ruthazer R et al. Missed diagnoses of acute cardiac ischemia in the emergency department. N Engl J Med 2000; 342: 116370.
  • 6
    Forberg JL, Henriksen LS, Edenbrandt L, Ekelund U. Direct hospital costs of chest pain patients attending the emergency department: a retrospective study. BMC Emerg Med 2006; 6: 28.
  • 7
    Scirica BM, Sabatine MS, Jarolim P et al. Assessment of multiple cardiac biomarkers in non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 Trial. Eur Heart J 2010; 31: 19932005.
  • 8
    Apple FS, Pearce LA, Chung A, Ler R, Murakami MM. Multiple biomarker use for detection of adverse events in patients presenting with symptoms suggestive of acute coronary syndrome. Clin Chem 2007; 53: 87481.
  • 9
    Reichlin T, Hochholzer W, Stelzig C et al. Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol 2009; 54: 608.
  • 10
    Reichlin T, Hochholzer W, Bassetti S et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 2009; 361: 85867.
  • 11
    Roux-Lombard P, Pagano S, Montecucco F, Satta N, Vuilleumier N. Auto-antibodies as emergent prognostic markers and possible mediators of ischemic cardiovascular diseases. Clin Rev Allergy Immunol 2010. [Epub ahead of print].
  • 12
    Vuilleumier N, Rossier MF, Pagano S et al. Anti-apolipoprotein A-1 IgG as an independent cardiovascular prognostic marker affecting basal heart rate in myocardial infarction. Eur Heart J 2010; 31: 81523.
  • 13
    Vuilleumier N, Bas S, Pagano S et al. Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 2010; 62: 264050.
  • 14
    Montecucco F, Vuilleumier N, Pagano S et al. Anti-apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability. Eur Heart J 2011; 32: 41221.
  • 15
    de Faire U, Su J, Hua X et al. Low levels of IgM antibodies to phosphorylcholine predict cardiovascular disease in 60-year old men: effects on uptake of oxidized LDL in macrophages as a potential mechanism. J Autoimmun 2010; 34: 739.
  • 16
    Gronlund H, Hallmans G, Jansson JH et al. Low levels of IgM antibodies against phosphorylcholine predict development of acute myocardial infarction in a population-based cohort from northern Sweden. Eur J Cardiovasc Prev Rehabil 2009; 16: 3826.
  • 17
    Antman EM, Cohen M, Bernink PJ et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 2000; 16: 284.
  • 18
    Vuilleumier N, Charbonney E, Fontao L et al. Anti-apolipoprotein A-1 IgG are associated with high oxidised low-density lipoprotein levels in acute coronary syndrome. Clin Sci (London) 2008; 115: 2533.
  • 19
    Thygesen K, Alpert JS, White HD. Joint ESC/ACCF/AHA/WHF task force for the redefinition of myocardial infarction. Universal definition of myocardial infarction. Eur Heart J 2007; 28: 252538.
  • 20
    DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 83745.
  • 21
    Pencina MJ, D’Agostino Sr RB, D’Agostino Jr RB, Vasan RS. Evaluating the added predictiveability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 15772.
  • 22
    Nendaz MR, Perrier A. Théorème de Bayes et rapports de vraisemblance. Rev Mal Respir 2004; 21: 3947.
  • 23
    Jiménez D, Uresandi F, Otero R et al. Troponin-based risk stratification of patients with acute non-massive pulmonary embolism: systematic review and meta-analysis. Chest 2009; 136: 97482.
  • 24
    Hanley JA, Mc Neil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 2936.
  • 25
    Pepe MS, Jane H, Longton G, Leisenring W, Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic or screening marker. Am J Epidemiol 2004; 159: 88290.
  • 26
    Cook NR. Methods for evaluating novel biomarkers – a new paradigm. Int J Clin Pract 2010; 64: 17237.
  • 27
    Vuilleumier N, Bratt J, Alizadeh R, Jogestrand T, Hafström I, Frostegård J. Anti-ApoA-1 IgG and oxidized LDL are raised in rheumatoid arthritis (RA): potential associations with cardiovascular disease and RA disease activity. Scand J Rheumatol 2010; 39: 44753.
  • 28
    Caligiuri G, Nicoletti A, Poirier B, Hansson GK. Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J Clin Invest 2002; 109: 74553.
  • 29
    Hess EP, Agarwal D, Chandra S et al. Diagnostic accuracy of the TIMI risk score in patients with chest pain in the emergency department: a meta-analysis. CMAJ 2010; 182: 103944.
  • 30
    Campbell CF, Chang AM, Sease KL et al. Combining thrombolysis in myocardial infarction risk score and clear-cut alternative diagnosis for chest pain risk stratification. Am J Emerg Med 2009; 27: 3742.
  • 31
    Vorlat A, Claeys MJ, De Raedt H et al. TIMI risk score underestimates prognosis in unstable angina/non-ST segment elevation myocardial infarction. Acute Card Care 2008; 10: 269.